Production (Stage)
Galera Therapeutics, Inc.
GRTX
$0.027
-$0.0056-17.18%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.66% | 67.91% | 71.85% | 58.80% | 29.05% |
| Total Depreciation and Amortization | -95.56% | -92.28% | 235.71% | 184.71% | 140.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.79% | -47.23% | -64.88% | -67.62% | -40.10% |
| Change in Net Operating Assets | 71.01% | 27.30% | -1,102.45% | -331.73% | -1,042.98% |
| Cash from Operations | 74.74% | 72.92% | 59.65% | 34.29% | 13.12% |
| Capital Expenditure | -- | -- | 82.00% | 83.64% | -391.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -84.76% | -28.80% | 14.14% |
| Cash from Investing | -100.21% | -100.17% | -84.75% | -28.65% | 13.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.99% | -93.49% | -- | -85.96% | -79.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | -- |
| Cash from Financing | -23.05% | -92.94% | -100.67% | -94.11% | -87.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.75% | -171.50% | -237.13% | -295.00% | -301.43% |